Clinical Trial

13-cis Retinoic Acid (Isotretinoin) and Sperm Production

Study acronym: ARESPERM
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the effectiveness of weekly administration of isotretinoin (40 mg) in increasing sperm production in men with oligozoospermia, a condition characterized by a low sperm count. Participants will be randomized into two groups: one receiving isotretinoin and the other a placebo. The primary outcome will be the change in sperm production over 20 weeks of treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-18.
Trial Details
NCT Number NCT06698263
Lead Sponsor University Hospital, Strasbourg, France
Conditions Men with Infertility
Enrollment 100 participants
Start Date 2025-03-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-25